Drug Trial Radar · NCT00910429
BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension
Last checked: Nov 20, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
237
Actual
Start
Jul 1, 2009
Primary completion
Aug 19, 2019
Study completion Aug 19, 2019
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- May 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348) will be asked to participate in this long term extension study with BAY63-2521. The aim of the long term study is to collect additional information to evaluate the safety and tolerability of BAY63-2521. Patients will be treated with open label medication on their individual optimal dose between 0,5 mg - 2,5 mg tid.
Conditions
- Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521)Drug
BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAE)Time frame: From administration of first dose of study medication up to 2 days after end of treatment with study medication, up to 10 years
- Number of Participants With DeathTime frame: From baseline to end of safety follow-up visit, up to 10 years (1 month more than End of study visit)
Locations
73 sites in 26 countries. Site status is shown where the registry gives one.
Site not named
La Jolla, California
Site not named
Sacramento, California
Site not named
Iowa City, Iowa
Site not named
Baltimore, Maryland
Site not named
Boston, Massachusetts
Site not named
Cleveland, Ohio
Site not named
Columbus, Ohio
Site not named
Dallas, Texas
Site not named
Corrientes, Argentina
Site not named
Prahran, Victoria, Australia
Site not named
Vienna, Austria
Site not named
Bruxelles - Brussel, Belgium
Site not named
Leuven, Belgium
Site not named
Rio de Janeiro, Brazil
Site not named
Porto Alegre, Rio Grande do Sul, Brazil
Site not named
São Paulo, São Paulo, Brazil
Site not named
Calgary, Alberta, Canada
Site not named
London, Ontario, Canada
Site not named
Ottawa, Ontario, Canada
Site not named
Toronto, Ontario, Canada
Site not named
Montreal, Quebec, Canada
Site not named
Beijing, China
Site not named
Beijing, China
Site not named
Shanghai, China
Site not named
Prague, Czechia
Site not named
Aarhus N, Denmark
Site not named
Brest, France
Site not named
Le Kremlin-Bicêtre, France
Site not named
Rouen, France
Site not named
Vandœuvre-lès-Nancy, France
Site not named
Hamburg, Germany
Site not named
Heidelberg, Baden-Wurttemberg, Germany
Site not named
München, Bavaria, Germany
Site not named
Würzburg, Bavaria, Germany
Site not named
Giessen, Hesse, Germany
Site not named
Hanover, Lower Saxony, Germany
Site not named
Cologne, North Rhine-Westphalia, Germany
Site not named
Homburg, Saarland, Germany
Site not named
Dresden, Saxony, Germany
Site not named
Leipzig, Saxony, Germany
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.